Medical Condition News

RSS

New RUB project to unravel role of enzyme Parkin in promoting neuronal survival

Cell biologists at the Ruhr-Universit-t Bochum have launched a new project to unravel the role of the enzyme Parkin in promoting neuronal survival. The team of Prof Dr Konstanze F. Winklhofer from the Institute of Physiological Chemistry, Department of Molecular Cell Biology, is looking for new therapeutic options to treat Parkinson's disease. The Michael J. Fox Foundation finances this research project with 125,000 US Dollars.

18 Dec 2013

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

The Ben & Catherine Ivy Foundation today announced a $3 million grant to the Translational Genomics Research Institute (TGen), Nemucore Medical Innovations Inc., and Barrow Neurological Institute at St. Joseph's Hospital and Medical Center to help fund significant brain tumor research in Arizona.

18 Dec 2013

Research adds debate about how human bodies respond to artificial sweeteners

New research from the University of Adelaide has added to the debate about how our bodies respond to artificial sweeteners and whether they are good, bad or have no effect on us.

18 Dec 2013

MSCs isolated from MS patients have decreased suppressive function

Multiple sclerosis, an inflammatory autoimmune disease affecting more than one million people worldwide, is caused by an immune reaction to myelin proteins, the proteins that help form the myelin insulating substance around nerves. Demyelination and MS are a consequence of this immune reaction. Bone marrow mesenchymal stem cells have been considered as an important source for cell therapy for autoimmune diseases such as MS because of their immunosuppressive properties.

18 Dec 2013

Researchers receive Special Challenge Award to investigate role of high protein levels in prostate tumors

Cleveland Clinic, along with the National Cancer Institute, the University of Chicago and Thomas Jefferson University, are the recipients of a $600,000 Special Challenge Award from the Prostate Cancer Foundation (PCF) to investigate the role of abnormally high protein levels in prostate tumors.

18 Dec 2013

Alexandria-based Prevent Cancer Foundation gets $5,000 grant from Cardinal Bank Community

Cardinal Bank announced today that the Cardinal Bank Community Fund has awarded $5,000 to the Prevent Cancer Foundation. The mission of the Alexandria-based organization is to save lives through cancer prevention and early detection, and it has provided more than $130 million to support cancer prevention, early detection research, education, advocacy, and community outreach nationwide.

18 Dec 2013

Merck signs license agreement with CNIO for cancer drug development

Merck Serono, the biopharmaceutical division of Merck, today announced that a license agreement has been signed with the Spanish National Cancer Research Centre in Madrid in the area of cancer drug development. The global agreement will build upon CNIO research discoveries to encourage the development and commercialization of new compounds in the field of oncology.

18 Dec 2013

Elekta to launch MOSAIQ oncology information system throughout McLaren's cancer network

The ability to effectively manage data across disparate health systems to help drive quality care will be a cornerstone for health systems of the future. Elekta is proud to announce today that it has joined forces with Michigan-based McLaren Health Care to launch MOSAIQ oncology information system throughout McLaren's cancer network.

From Elekta 18 Dec 2013

Mylan obtains exclusive rights from Pfizer to develop, commercialize novel LAMA compound

Mylan Inc. today announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist compound for various indications.

18 Dec 2013

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today enrollment of the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland, a world-leading site for celiac disease research. Results are expected in mid-2014.

18 Dec 2013

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Merck, known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company's investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline's orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma.

18 Dec 2013

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema.

18 Dec 2013

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Omeros Corporation today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration for prevention of complement-mediated thrombotic microangiopathies.

18 Dec 2013

Primary cilia play key role in stem cell differentiation

Researchers at Queen Mary University of London have shown for the first time that the specialised role stem cells go on to perform is controlled by primary cilia -tiny hair-like structures protruding from a cell.

18 Dec 2013

Researchers develop potential treatment for atherosclerosis

Researchers at Emory and Georgia Tech have developed a potential treatment for atherosclerosis that targets a master controller of the process.

18 Dec 2013

Octapharma enrolls first patients in GAM-27 Phase II/III clinical trial for relapsing multiple sclerosis

Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis. Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.

18 Dec 2013

NUS scientists open possible new route for treatment of spinal muscular atrophy

A recent study led by scientists from the National University of Singapore (NUS) opens a possible new route for treatment of Spinal Muscular Atrophy (SMA), a devastating disease that is the most common genetic cause of infant death and also affects young adults.

18 Dec 2013

ASH and ISH release guidelines for diagnosis and treatment of hypertension

High blood pressure affects approximately one in three adults in the Americas, Europe, some Asian countries and Australia, and one billion people worldwide.

18 Dec 2013

Research examines link between opioid suppression of immune system and cancer recurrence

The methods used to anesthetize prostate cancer patients and control pain when their prostate glands are surgically removed for adenocarcinoma may affect their long-term cancer outcomes, a study led by Mayo Clinic has found.

18 Dec 2013

Study identifies atrial fibrillation as a growing and serious global health problem

Atrial fibrillation, long considered the most common condition leading to an irregular heartbeat, is a growing and serious global health problem, according to the first study ever to estimate the condition's worldwide prevalence, death rates and societal costs.

18 Dec 2013

Medical Condition News

New RUB project to unravel role of enzyme Parkin in promoting neuronal survival

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

Research adds debate about how human bodies respond to artificial sweeteners

MSCs isolated from MS patients have decreased suppressive function

Researchers receive Special Challenge Award to investigate role of high protein levels in prostate tumors

Alexandria-based Prevent Cancer Foundation gets $5,000 grant from Cardinal Bank Community

Merck signs license agreement with CNIO for cancer drug development

Elekta to launch MOSAIQ oncology information system throughout McLaren's cancer network

Mylan obtains exclusive rights from Pfizer to develop, commercialize novel LAMA compound

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Primary cilia play key role in stem cell differentiation

Researchers develop potential treatment for atherosclerosis

Octapharma enrolls first patients in GAM-27 Phase II/III clinical trial for relapsing multiple sclerosis

NUS scientists open possible new route for treatment of spinal muscular atrophy

ASH and ISH release guidelines for diagnosis and treatment of hypertension

Research examines link between opioid suppression of immune system and cancer recurrence

Study identifies atrial fibrillation as a growing and serious global health problem

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News